Cargando…

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

Chronic lymphocytic leukemia is characterized by impaired immune functions largely due to profound T-cell defects. T-cell functions also depend on co-signaling receptors, inhibitory or stimulatory, known as immune checkpoints, including cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and progra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palma, Marzia, Gentilcore, Giusy, Heimersson, Kia, Mozaffari, Fariba, Näsman-Glaser, Barbro, Young, Emma, Rosenquist, Richard, Hansson, Lotta, Österborg, Anders, Mellstedt, Håkan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394965/ https://www.ncbi.nlm.nih.gov/pubmed/27927767 http://dx.doi.org/10.3324/haematol.2016.151100

Ejemplares similares

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016)

Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
por: Lundin, Jeanette, et al.
Publicado: (2021)

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
por: Kokhaei, Parviz, et al.
Publicado: (2018)

P609: EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.
por: Andersson, Maria, et al.
Publicado: (2023)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
por: Andersson, Maria, et al.
Publicado: (2023)

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
por: Mulder, Tom A., et al.
Publicado: (2022)

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2017)

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
por: Palma, Marzia, et al.
Publicado: (2021)

Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
por: Mattsson, Agnes, et al.
Publicado: (2020)

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
por: Daneshmanesh, Amir Hossein, et al.
Publicado: (2018)

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
por: Mulder, Tom A., et al.
Publicado: (2021)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1(+) CLL cells
por: Ghaderi, Amineh, et al.
Publicado: (2021)

A Proline/Arginine-Rich End Leucine-Rich Repeat Protein (PRELP) Variant Is Uniquely Expressed in Chronic Lymphocytic Leukemia Cells
por: Mikaelsson, Eva, et al.
Publicado: (2013)

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
por: Karlsson, C, et al.
Publicado: (2011)

Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells
por: Mikaelsson, Eva, et al.
Publicado: (2013)

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
por: Hansson, Lotta, et al.
Publicado: (2017)

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
por: Hojjat-Farsangi, M., et al.
Publicado: (2018)

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID‐19 in chronic lymphocytic leukaemia?
por: Smith, Carl Inge Edvard, et al.
Publicado: (2022)

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
por: Blixt, Lisa, et al.
Publicado: (2021)

Clinical considerations for biosimilar antibodies
por: Mellstedt, Håkan
Publicado: (2013)

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
por: Mozaffari, F, et al.
Publicado: (2007)

Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
por: Olsson, A, et al.
Publicado: (2007)

Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
por: Mulder, Tom A., et al.
Publicado: (2019)

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
por: Ghaderi, Amineh, et al.
Publicado: (2022)

P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
por: Mulder, T. A., et al.
Publicado: (2022)

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production
por: Gentilcore, Giusy, et al.
Publicado: (2014)

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
por: Pico de Coaña, Yago, et al.
Publicado: (2015)

Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis.
por: Wedelin, C., et al.
Publicado: (1982)

Dysregulation of T Lymphocyte Proliferative Responses in Autoimmunity
por: Elizer, Sydney K., et al.
Publicado: (2014)

Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis
por: Li, Wei, et al.
Publicado: (2020)

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
por: Pittari, Gianfranco, et al.
Publicado: (2015)

Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes
por: Kursunel, M. Alper, et al.
Publicado: (2021)

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
por: Blixt, Lisa, et al.
Publicado: (2022)

NF-κB as potential target in the treatment of melanoma
por: Madonna, Gabriele, et al.
Publicado: (2012)

Precision diagnostics in chronic lymphocytic leukemia: Past, present and future
por: Mollstedt, John, et al.
Publicado: (2023)

Rheumatoid arthritis patients display B-cell dysregulation already in the naïve repertoire consistent with defects in B-cell tolerance
por: Wang, Yan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_73qelu3giqhreuaqqjosfv1vab